###### Key messages

What is already known about this subject?
=========================================

-   There is limited evidence on the outcomes of COVID-19 in patients with rheumatic diseases and the impact of age, comorbidity, therapy or other factors associated to severity specifically in these patients.

What does this study add?
=========================

-   We found that severe COVID-19 occurred in 31.6% of the rheumatic and 28.1% of non-rheumatic cohorts.

-   Having a connective tissue disease but not its therapy was significantly associated with severe COVID-19.

-   Other known risk factors as ageing or male sex also apply to patients with rheumatic diseases.

How might this impact on clinical practice or future developments?
==================================================================

-   These findings have important implications to guide COVID-19 recommendations to specific groups of patients with rheumatic diseases and to provide evidence-based advice on the importance of maintaining therapies.

INTRODUCTION {#s1}
============

The clinical spectrum of SARS-CoV-2 infection is quite broad, ranging from asymptomatic to life-threatening or fatal disease. Different factors have been associated with poor prognosis, including older age, gender and pre-existing comorbidities such as diabetes, hypertension and lung and cardiovascular disease.[@R1] Immune-mediated diseases and immunosuppressive therapies increase the susceptibility to viral and bacterial infections, and therefore, understanding how COVID-19 impacts on these patients is an urgent need.[@R4]

Since severe COVID-19 is associated with a hyperinflammatory process, it is of particular interest to investigate how pre-existing inflammatory diseases or the previous use of immunosuppressive agents influence COVID-19 expression.[@R7] We have previously reported an increased prevalence of hospital attended COVID-19 in patients with connective tissue diseases (CTDs) and in patients treated with targeted synthetic or biologic disease-modifying antirheumatic drug (ts/bDMARD) therapy compared with a reference population, reflecting either increased risk of infection or increased severity.[@R8] In the largest COVID-19 series, neither CTD nor immunosuppressive therapies were represented, but incompleteness of information on these specific factors is possible.[@R1] In a recent report of a small cohort of hospitalised patients with rheumatic diseases, a higher need for mechanical ventilation compared with non-rheumatic controls was found, whereas in another similar series no differences with controls were found.[@R9] A global registry of patients with rheumatic diseases found glucocorticoids (GCs) but not other therapies associated with a higher risk for hospitalisation.[@R11] In patients with inflammatory bowel disease, GC but not anti-tumour necrosis factor-α (anti-TNF-α) drugs independently increase the risk of severe disease.[@R12] Other immunosuppressed patients, as solid organ transplanted, have more severe COVID-19; however, the role of age or comorbidities and the lack of controls do not permit to draw definitive conclusions.[@R13]

An additional concern among rheumatologists is that in most chronic inflammatory rheumatic diseases, clinical and subclinical metabolic and cardiovascular comorbidity is increased, which may also put these patients at higher risk of poor outcomes.[@R15] It is therefore necessary for contingency prevention plans to identify vulnerable patients and specific features at high risk requiring special vigilance or management.

We undertook a multicentric comparative cohort study to investigate the relationship between underlying rheumatic disease and COVID-19 outcomes and to identify specific risk factors associated with poor outcomes.

Patients and methods {#s2}
====================

We performed a retrospective observational matched cohort study from the databases of five reference centres pertaining to a public research network for the investigation of inflammation and rheumatic diseases (RIER, <https://red-rier.org/>). Each of the included centres has accessibility to updated medical record ID lists of adult patients under follow-up in rheumatology departments and was a reference centre for microbiology, where all SARS-CoV-2 PCR diagnostic tests in the covered population were performed. Patients' medical record IDs were matched against central SARS-CoV-2+PCR hospital registers up to 17 April, just after the incidence peak of SARS-CoV-2 infection had been reached in Spain [(https://cnecovid.isciii.es/COVID-19](https://cnecovid.isciii.es/COVID-19)). Electronic medical records were reviewed to confirm COVID-19 diagnosis and to obtain clinical data. Since at that time, availability of CoV-2 PCR testing was limited due to shortages, these registries only include patients attending referral hospitals and exclude the less severe community cases that did not require hospitalisation nor referral to hospitals' emergency departments.

The rheumatology cohort included all adult patients diagnosed with chronic inflammatory arthritis (IA), including rheumatoid arthritis, psoriatic arthritis (PsA) and spondyloarthritis (SpA); CTD, including systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), systemic sclerosis, polymyalgia rheumatica (PMR), vasculitides and so on ([online supplementary table S1](#SP1){ref-type="supplementary-material"}) with a PCR+COVID-19 diagnosis. The control cohort was assembled from the Microbiology databases of the participating centres matched on a 1:1 basis with the rheumatic cohort on the date of COVID-19 diagnosis ('index date'), sex and age, and blinded to outcome or other variables. In this control cohort, patients with CTD were excluded.
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Variables and measurements {#s2-1}
--------------------------

We collected the following data from the electronic health record to describe COVID-19 evolution: evidence of pneumonia by plain X-ray, respiratory insufficiency, oxygen necessities (collected as ordinal variable ranging from 0 'no external oxygen required', to 1 'oxygen by nasal cannula', 2 'reservoir', 3 'non-invasive ventilation' and 4 'tracheal intubation'), serious complications (including myocarditis or heart failure, encephalopathy, thrombosis, kidney failure and septic shock as defined in [online supplementary information](#SP1){ref-type="supplementary-material"}), duration of admission and death. Laboratory data were also collected at baseline and at peak levels for the following variables: C reactive protein (CRP), interleukin-6 (IL-6), lymphocyte counts, D-dimer, lactate dehydrogenase and ferritin.

The primary outcome was a composite outcome, 'severe COVID-19', including death, intensive care unit admission, intratracheal intubation or serious COVID-19 complications as previously enumerated. The definitions of these complications are described in [online supplementary information](#SP1){ref-type="supplementary-material"}.

Factors studied in relation to the outcome were those common to all patients with COVID-19, such as age (with a cut-off at 60 years), male sex, cardiovascular disease, obesity, diabetes, hypertension and lung disease. Specific factors for rheumatic diseases included diagnostic group, disease duration, treatments---such as GCs, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), other immunosuppressants (including azathioprine, cyclophosphamide, mofetil mycophenolate and calcineurin inhibitors), or ts/bDMARD, including Jakinibs (tofacitinib or baricitinib), or any biological agents (TNF-α, IL-1, IL-6 or IL-23/IL-17 antagonists, abatacept or rituximab). COVID-19 treatment was also collected and treated as potentially confounding covariate. The most commonly used treatments were hydroxychloroquine, antivirals (lopinavir/ritonavir and remdesivir), GC and anticytokines. We used summary statistics to describe the cohorts, and t tests, χ^2^, Fisher's exact and log rank tests to refute hypothetical differences between them. For time to variables, we used 15 May as censor date.

We then estimated the risk of developing severe COVID-19 in each cohort, in terms of point estimates and 95% CIs, risk difference, risk ratio and attributable fractions for the rheumatic and total population. The relative risk of prognostic factors was estimated, and the hypothesis of an effect modification of having a CTD rheumatic disease tested with the Mantel-Haenszel method.

Subsequently, we run bivariable and multivariable logistic regression models to assess the association between rheumatic diseases and severe COVID-19 in detail, where the composite outcome was the dependent variable. We used several approaches to building the models: (1) using the *allsets* command, (2) automatic backward stepwise starting with a full model with all variables with a p value \<0.25 in the bivariable and (3) a manual stepwise method, keeping cohort and confounding variables in the model. The best model was selected on the basis of the Akaike information criterion and the Bayesian information criterion, and the area under the receiver operating characteristic (ROC) curve and predictive capacity of the best model estimated as described.[@R17] All analyses were done in Stata V.12.

All data were anonymised.

Results {#s3}
=======

The total sample was 456, evenly distributed into 228 patients per cohort. The diagnoses of patients with rheumatic diseases were IA (n=136, 60%): RA (n=65, 29%), SpA (n=35, 16%), PsA (n=36, 15%) and CTD (92, 40%) as detailed in [online supplementary table S1](#SP1){ref-type="supplementary-material"}. The mean duration of the rheumatic disease was 10 years (SD 8.3) with no differences across diseases.

[Table 1](#T1){ref-type="table"} shows a description of both cohorts. These were matched in terms of age and sex, and well balanced regarding most other variables. However, clinician-reported only refers to obesity, and cardiovascular disease were more frequent among patients with rheumatic diseases versus controls.

###### 

Description of the cohorts compared

  Characteristics           n     Non-rheumatic n=228   Rheumatic n=228   P value
  ------------------------- ----- --------------------- ----------------- ---------
  Age, median (IQR)         456   65 (53--77)           63 (54--78)       0.865
  Age \>60 years            456   132 (57.9)            127 (55.7)        0.636
  Male sex                  456   95 (41.7)             87 (38.2)         0.444
  Comorbidity                                                             
   Obesity                  451   38 (16.6)             71 (31.7)         \<0.001
   Diabetes                 456   39 (17.1)             46 (20.2)         0.400
   Hypertension             455   99 (43.4)             111 (48.9)        0.241
   Cardiovascular disease   455   42 (18.4)             64 (28.2)         0.014
   Lung disease             455   48 (21.1)             45 (19.8)         0.745

Values in cells represent n (%) unless otherwise indicated.

Regarding treatments previously used by patients with rheumatic diseases that could predispose them to infection, most patients were on csDMARDs (57%), followed by GCs (40%), biologic agents (23%), mostly TNF-α antagonists and 12% on other immunosuppressants ([table 2](#T2){ref-type="table"}) before the onset of COVID-19 symptoms. In most patients (86%) on any immunosuppressant therapy but GC, including methotrexate and leflunomide among csDMARD or any ts/bDMARD (n=125 with this information available), it was withdrawn either at symptom onset or at hospital admission. Physician-reported activity of the different rheumatic diseases (active or on remission) by diagnostics is described in [online supplementary table S1](#SP1){ref-type="supplementary-material"}.

###### 

Baseline therapies of patients with rheumatic diseases

  Treatment                            n (%)
  ------------------------------------ ------------
  Glucocorticoids                      91 (40.1)
   Dose\*, m±SD when taken             9.9±11.5
   \>10 mg/day prednisone equivalent   15 (6.6)
  csDMARD                              129 (56.6)
   Methotrexate                        64 (28.1)
   Antimalarial drugs                  28 (12.4)
   Leflunomide                         20 (8.9)
   Sulfasalazine                       17 (7.5)
  Other immunosuppressants             28 (12.3)
   Mofetil mycophenolate               12 (5.3)
   Azathioprine                        7 (3.1)
   Cyclophosphamide                    2 (0.8)
   Calcineurin inhibitors              7 (3.1)
  ts/bDMARD                            53 (23.2)
   TNF-α antagonists                   35 (15.4)
   Rituximab                           5 (2.2)
   IL-17/IL-23 antagonists             4 (1.8)
   Abatacept                           3 (1.3)
   Tocilizumab                         2 (0.8)
   Sarilumab                           1 (0.4)
   Tofacitinib                         3 (1.3)

\*In mg/day of prednisone equivalents.

csDMARD, conventional synthetic disease-modifying antirheumatic drug; IL, interleukin; TNF, tumour necrosis factor; ts/bDMARD, targeted synthetic or biological disease-modifying antirheumatic drug.

No patient in the non-rheumatic cohort was taking any of these drugs, except for a patient who was taking GC at a dose of 5 mg/day for other reasons.

The evolution of the COVID-19 disease and its comparison between cohorts are described in [table 3](#T3){ref-type="table"}. The bivariable analysis shows a larger proportion of radiographic pneumonia in the non-rheumatic cohort and a non-statistically larger proportion of heart failure and higher peak serum creatinine in the rheumatic cohort. All other variables measured were similar between groups, which were also treated with similar COVID-19 drugs, with the exception of a non-statistically significant larger use of azithromycin in the non-rheumatic cohort.

###### 

Description of evolution and therapy of COVID-19 in the compared cohorts

  COVID-19 evolution                n     Non-rheumatic n=228   Rheumatic n=228   P value
  --------------------------------- ----- --------------------- ----------------- ---------
  No days before PCR+\*             428   7.9±6.0               7.0±6.4           0.117
  Radiographic pneumonia            443   183 (83.2)            154 (69.1)        \<0.001
  Hospitalisation                   455   175 (77.1)            162 (71.1)        0.142
  Duration of hospital stay\*       267   12.6±10.0             12.0±8.7          0.626
  Respiratory insufficiency         455   143 (62.7)            128 (56.4)        0.169
  ICU admission                     453   16 (7.1)              15 (6.7)          0.882
  Respiratory category              453                                           0.103
   No oxygen was necessary                96 (42.1)             100 (44.4)        
   Oxygen by nasal cannula                99 (43.4)             103 (45.8)        
   Oxygen with reservoir                  14 (6.1)              3 (1.3)           
   Non-invasive ventilation               13 (5.7)              11 (4.9)          
   Invasive ventilation                   6 (2.6)               8 (3.6)           
  Significant complications         452   55 (24.1)             63 (28.1)         0.333
   Heart failure                    448   4 (1.8)               11 (5.0)          0.056
   Encephalopathy                   449   8 (3.5)               3 (1.4)           0.140
   Thrombotic event                 448   6 (2.6)               6 (2.7)           0.962
   Kidney failure                   449   32 (14.0)             30 (13.6)         0.888
   Septic shock                     447   11 (4.8)              15 (6.9)          0.361
  Death                             455   30 (13.2)             41 (18.1)         0.150
   Days from first symptom\*        431   52.0±17.9             47.6±19.5         0.191
  Severe COVID-19†                  456   64 (28.1)             72 (31.6)         0.413
  Laboratory tests (peak value)\*                                                 
   C reactive protein (mg/dL)       386   12.5±12.0             11.0±10.1         0.199
   IL-6 (μg/mL)                     87    496±1990              134±8535          0.268
   Lymphocytes (cells/μL)           386   903±480               993±1586          0.445
   D-dimer (μg/L)                   291   2356±5605             2505±10 769       0.883
   Serum creatinine (mg/dL)         375   1.0±0.7               1.2±1.1           0.030
   Lactate dehydrogenase (U/L)      355   390±210               377±174           0.558
   Ferritin (μg/L)                  207   1056±1098             1201±2244         0.551
  COVID-19 therapy                                                                
   Hydroxychloroquine               450   172 (76.1)            157 (70.1)        0.150
   Azithromycin                     450   128 (56.6)            103 (46.0)        0.024
   Antivirals                                                                     
   Lopinavir/ritonavir              449   94 (41.8)             86 (38.4)         0.464
   Remdesivir                       450   2 (0.9)               2 (0.9)           0.685
   Glucocorticoids                  449   53 (23.5)             57 (25.6)         0.603
   Anticytokines                    456   24 (10.5)             16 (7.1)          0.185
   IL-6 inhibitors                  448   22 (9.8)              15 (6.7)          0.241
   IL-1 inhibitors                  449   2 (0.9)               3 (1.4)           0.684
   Jakinibs                         450   1 (0.4)               1 (0.5)           1.000
   Intravenous immunoglobulin       449   --                    1 (0.5)           0.314

Values in cells represent n (%) unless otherwise indicated.

\*Mean±SD.

†Death, ICU admission or serious COVID-19 complication.

ICU, intensive care unit; IL, interleukin.

The risk of a severe COVID-19 was 28.1% in the non-rheumatic cohort and 31.6% in the rheumatic cohort, that is, a risk difference of 3.5% (95% CI −4.9% to 11.9%), a risk ratio of 1.13 (95% CI 0.84 to 1.49), an attributable fraction of the exposed of 11.1% and in the population of 5.9% (p=0.413).

[Table 4](#T4){ref-type="table"} shows the relative risk of variables common to both cohorts, by cohort. Age ≥60 years and all comorbid variables were associated with outcome in the rheumatic cohort, but only age, hypertension and lung disease in the non-rheumatic cohort. No clear effect modification of the cohort on the associations was present, as by the results of the homogeneity test.

###### 

Analysis of individual risk factors for poor outcome: total and by cohort

  Variable            Relative risk (95% CI)    P value\*                 
  ------------------- ------------------------- ------------------------- -------
  Age over 60 years   **3.70 (1.99 to 6.93)**   **4.04 (2.30 to 7.08)**   0.841
  Male sex            **2.16 (1.39 to 3.35)**   **1.58 (1.09 to 2.29)**   0.286
  Obesity             1.22 (0.72 to 2.06)       **1.62 (1.10 to 2.36)**   0.393
  Diabetes            0.95 (0.53 to 1.70)       **1.93 (1.34 to 2.79)**   0.038
  Hypertension        **1.64 (1.07 to 2.53)**   **2.27 (1.49 to 3.46)**   0.290
  CV disease          1.44 (0.90 to 2.33)       **2.92 (2.04 to 4.17)**   0.020
  Lung disease        **1.57 (1.00 to 2.46)**   **1.74 (1.19 to 2.55)**   0.723

Bold values indicate statistically significant associations with outcome.

\*From a Mantel-Haenszel test of homogeneity. If p\<0.01, the cohort of origin is modifying the effect.

CV, cardiovascular.

The results of the bivariable and multivariable logistic regression analysis are shown in [table 5](#T5){ref-type="table"}. Variables with very low observations were not analysed or combined into meaningful categories. The best model was the stepwise automatic one, in which specific variables were forced in (obesity, diabetes, heart failure and GCs) to adjust results for, and its results are shown in the right part of the table and in [figure 1](#F1){ref-type="fig"}. The model correctly classified 72.23% of the patients (area under the ROC curve=0.753).

###### 

Association of risk factors with poor outcome in COVID-19

  ----------------------------------------------------------------------------------------------
  Factors                       OR (95% CI)\           P value   OR (95% CI)\          P value
                                Bivariable                       Multivariable         
  ----------------------------- ---------------------- --------- --------------------- ---------
  Rheumatic disease             1.29 (0.86 to 1.93)    0.218                           

   CTD                          1.64 (1.02 to 2.66)    0.042     1.82 (1.00 to 3.30)   0.050

   Chronic IA                   0.90 (0.58 to 1.41)    0.659                           

  Age \>60 years                6.06 (3.65 to 10.06)   \<0.001   4.83 (2.78 to 8.37)   \<0.001

  Male sex                      2.34 (1.55 to 3.53)    \<0.001   1.93 (1.21 to 3.07)   0.006

  Comorbidity                                                                          

   Obesity                      1.78 (1.13 to 2.81)    0.013     1.47 (0.86 to 2.51)   0.164

   Diabetes                     1.81 (1.11 to 2.95)    0.018     0.82 (0.46 to 1.46)   0.493

   Hypertension                 2.60 (1.72 to 3.94)    \<0.001                         

   Heart failure                3.49 (2.21 to 5.51)    \<0.001   1.57 (0.93 to 2.66)   0.092

   Lung disease                 2.15 (1.34 to 3.45)    0.001                           

  Medication                                                                           

   Glucocorticoids (any dose)   2.20 (1.36 to 3.54)    0.001     1.10 (0.60 to 2.01)   0.755

   HCQ                          1.15 (0.51 to 2.62)    0.733                           

   csDMARDs                     1.04 (0.64 to 1.72)    0.864                           

   ts/bDMARDs                   0.45 (0.21 to 0.96)    0.039                           

   Other IS                     0.99 (0.40 to 2.44)    0.981                           

  COVID-19 drugs used                                                                  

   HCQ                          2.26 (1.35 to 3.79)    0.002                           

   Antivirals                   2.37 (1.58 to 3.59)    \<0.001   2.05 (1.30 to 3.23)   \<0.001
  ----------------------------------------------------------------------------------------------

csDMARD, conventional synthetic disease-modifying antirheumatic drug; CTD, connective tissue disease; HCQ, hydroxychloroquine; IA, inflammatory arthritis; IS, immunosuppressants; ts/bDMARD, targeted synthetic or biological disease-modifying antirheumatic drug.

![ORs with 95% CIs of the best fitted model to predict 'severe COVID-19', adjusted for selected comorbidities and glucocorticoids use. CV, cardiovascular; CTD, connective tissue disease.](annrheumdis-2020-218296f01){#F1}

An independent association between CTD (OR 1.82; CI 1.00 to 3.30), age (OR 4.83; CI 2.78 to 8.37) and male sex (OR 1.93; CI 1.21 to 3.07) with higher risks for the composite severe COVID-19 outcome was found, whereas all other factors such as IA, comorbidities and active antirheumatic therapies were not confirmed in the multivariable adjusted analysis. A higher use of antivirals also remained associated to severity.

Since IA, and particularly CTD, include a heterogeneous group of patients with different diagnostics, we performed a subanalysis of groups with more homogeneous categories in terms of clinical or pathophysiological characteristics. By multivariable analysis, these four groups: SpA (including PsA); RA; SLE, SS and primary antiphospholipid syndrome (PAPS); and PMR, giant cell arteritis (GCA) and vasculitis showed a similar association as IA or CTD groups where they had been included ([online supplementary tables S2 and S3](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this matched cohort study, we show that among hospital patients with chronic inflammatory rheumatic diseases, having a systemic CTD but not an IA is an independent risk factor for poor COVID-19 outcomes. Comorbidities associated with severe COVID-19 in the general population are also associated with greater risk to these patients by bivariable analyses.[@R1] This is of particular interest because some of them as cardiovascular disease or obesity are also associated with inflammatory disease as shown in our cohort.[@R16] However, there was no independent association between these morbidities and severity in the fully adjusted multivariable analysis, suggesting some collinearity mainly with ageing and also with inflammatory disease.

Our data are in agreement with a previous study in a smaller COVID-19 hospitalised cohort, which identified a higher odds of intensive care admission/mechanical ventilation among hospitalised patients with rheumatic diseases versus matched controls.[@R9] In contrast with ours, this study combined all patients with IA and CTD. Our data illustrate how IA and CTD groups carry a different risk for severe COVID-19. Whether specific diagnostics within the heterogeneous CTD group may have a different risk cannot be ruled out. Our subanalysis of different groups such as vasculitides (including PMR/GCA) and SLE and related conditions showed similar associations with severe COVID-19 but further analyses would be needed to more precisely evaluate the severity of specific CTD.

Concerning previous use of therapies by patients with rheumatic diseases, the use of GC was associated with poorer outcome by bivariable analysis, whereas no substantial risk was detected neither for traditional immunosuppressants nor csDMARDS (methothrexate and leflunomide), nor for ts/bDMARD (mostly anti-TNF-α). Interestingly, the use of ts/bDMARD was associated in the bivariable with lower odds of complications. They did not make it into the final models probably because of the collinearity with other variables and not being the full rheumatic sample included, thus encountering problems of statistical power.

The potential therapeutic effect of anticytokine biologicals and Jakinibs on COVID-19 is being tested through numerous observational and randomised trials.[@R19] Since most of these drugs have long-term immunological effects even if withdrawn, their previous use in patients with rheumatic diseases might have a different influence on COVID-19 evolution than their use as therapy for COVID-19 acute inflammatory complications in non-rheumatic patients. In our previous analysis of the prevalence of hospital PCR+cases in patients with rheumatic diseases and the general population, a higher prevalence was observed in ts/bDMARD but not csDMARD-treated patients.[@R8] Therefore, our observations regarding ts/bDMARD should be considered with caution because we cannot exclude the possibility of confounding by indication of the therapies in the different included diseases, that is, the preferential use of ts/bDMARD in IA. Larger cohorts of patients treated with these drugs or meta-analysis are warranted to clarify the real impact of ts/bDMARD on COVID-19 susceptibility or severity in patients with rheumatic diseases.

Our study has additional limitations. Our conclusions are limited to hospitalised cases, excluding a large proportion of patients with rheumatic diseases with less severe COVID-19. As patients with rheumatic diseases and matched controls were selected on the same date, we do not expect to have selection bias on the initial patient's and control profiles.

Also, the role of the use of antivirals remains unclear. Although it was associated with worse outcome, a strong bias by its indication for the most severe patients seems the most plausible interpretation, since the most used drug (lopinavir/ritonavir) has resulted neither efficacious nor deleterious in randomised trials.[@R20]

Since ageing and having a CTD are the most relevant risk factors for severe COVID-19 in patients with rheumatic disease, shared immune-pathogenetic factors that might modify defensive and inflammatory responses need to be identified. Exhaustion of adaptive T-cell responses and increased effector inflammatory responses associated to accumulation of senescent cells, termed inflammaging, have been identified in both situations.[@R21] In experimental models of murine coronavirus infection, biological ageing induced by telomere dysfunction is also associated with lethality and higher cytokine responses.[@R24] In our cohorts, additional differences between rheumatic and control patients in the expression of COVID-19 were not detected. Despite the proinflammatory background of patients with CTD, the biological response to the infection is similar to that of controls in most studies.[@R9] This suggests that the severity is not necessarily related to quantitative differences in the cytokines response (ie, IL-6/CRP) and additional factors should be searched for.

In conclusion, among hospitalised patients with inflammatory rheumatic diseases, having a CTD pose a significantly greater risk for poor outcomes, whereas immunosuppressive therapies do not. Previously known risk factors as ageing and male sex also apply to patients with rheumatic diseases. This observation should help to tailor recommendations to specific diagnostic and therapeutic groups of patients with rheumatic diseases during this or future coronavirus pandemics.
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